NCCN Backs Molecular Testing for Prostate Cancer Patients in Certain Risk Groups

The National Comprehensive Cancer Network has updated prostate cancer guidelines to recommend biomarker testing for patients with unfavorable intermediate or high risk for aggressive disease.

Specifically, in the new version of the guidelines, issued on March 16, the NCCN states that men with unfavorable intermediate-risk and high-risk disease with a life expectancy of 10 years or longer can consider the use of Myriad Genetics’ Prolaris test or GenomeDx Biosciences’ Decipher test. Both molecular tests gauge the aggressiveness of patients’ cancer. Previously, the NCCN “not routinely recommended” molecular testing for intermediate-risk and high-risk groups.

 

Source: https://www.genomeweb.com/molecular-diagnostics/nccn-backs-molecular-testing-prostate-cancer-patients-certain-risk-groups